Cargando…

Cytogenetics’ impact on the prognosis of acute myeloid leukemia

INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Monika, Mahapatra, Manoranjan, Saxena, Renu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543945/
https://www.ncbi.nlm.nih.gov/pubmed/31160852
http://dx.doi.org/10.4103/JLP.JLP_164_18
_version_ 1783423170656600064
author Gupta, Monika
Mahapatra, Manoranjan
Saxena, Renu
author_facet Gupta, Monika
Mahapatra, Manoranjan
Saxena, Renu
author_sort Gupta, Monika
collection PubMed
description INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to therapy and the identification of an early reemergence of disease. MATERIALS AND METHODS: Newly diagnosed cases of AML were included in the study. Diagnosis of AML was based on morphology on bone marrow (BM) aspirates, cytochemistry, and flow cytometric immunophenotyping. Chromosomal analysis was performed on BM by short-term unstimulated cultures using standard cytogenetic technique. RESULTS: There were 25 males and 13 females with age group between 15 and 64 years. Cytogenetic analysis of these cases showed normal karyotype in 10 (26.3%) cases and abnormal karyotype in 28 (73.6%) cases. Cytogenetic finding in AML was divided into three groups: favorable risk, intermediate risk, and unfavorable risk. Patients in the standard risk group responded well to the chemotherapy while patients with intermediate and unfavorable karyotype had relapsed. CONCLUSION: We recommend that cytogenetics should be performed routinely in all cases of AML. A correlation must be done with various biochemical and hematological parameters, immunophenotyping, and BM morphology. Molecular studies must be integrated with cytogenetic studies for risk stratification at diagnosis to improve therapeutic strategies.
format Online
Article
Text
id pubmed-6543945
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-65439452019-06-03 Cytogenetics’ impact on the prognosis of acute myeloid leukemia Gupta, Monika Mahapatra, Manoranjan Saxena, Renu J Lab Physicians Original Article INTRODUCTION: Acute myeloid leukemia (AML) is a group of disorders characterized by a spectrum of clinical, morphological, immunophenotypic, and associated chromosomal abnormalities. The identification of cytogenetic abnormalities at diagnosis is important for the evaluation of the response to therapy and the identification of an early reemergence of disease. MATERIALS AND METHODS: Newly diagnosed cases of AML were included in the study. Diagnosis of AML was based on morphology on bone marrow (BM) aspirates, cytochemistry, and flow cytometric immunophenotyping. Chromosomal analysis was performed on BM by short-term unstimulated cultures using standard cytogenetic technique. RESULTS: There were 25 males and 13 females with age group between 15 and 64 years. Cytogenetic analysis of these cases showed normal karyotype in 10 (26.3%) cases and abnormal karyotype in 28 (73.6%) cases. Cytogenetic finding in AML was divided into three groups: favorable risk, intermediate risk, and unfavorable risk. Patients in the standard risk group responded well to the chemotherapy while patients with intermediate and unfavorable karyotype had relapsed. CONCLUSION: We recommend that cytogenetics should be performed routinely in all cases of AML. A correlation must be done with various biochemical and hematological parameters, immunophenotyping, and BM morphology. Molecular studies must be integrated with cytogenetic studies for risk stratification at diagnosis to improve therapeutic strategies. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6543945/ /pubmed/31160852 http://dx.doi.org/10.4103/JLP.JLP_164_18 Text en Copyright: © 2019 Journal of Laboratory Physicians http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Gupta, Monika
Mahapatra, Manoranjan
Saxena, Renu
Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title_full Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title_fullStr Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title_full_unstemmed Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title_short Cytogenetics’ impact on the prognosis of acute myeloid leukemia
title_sort cytogenetics’ impact on the prognosis of acute myeloid leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543945/
https://www.ncbi.nlm.nih.gov/pubmed/31160852
http://dx.doi.org/10.4103/JLP.JLP_164_18
work_keys_str_mv AT guptamonika cytogeneticsimpactontheprognosisofacutemyeloidleukemia
AT mahapatramanoranjan cytogeneticsimpactontheprognosisofacutemyeloidleukemia
AT saxenarenu cytogeneticsimpactontheprognosisofacutemyeloidleukemia